Mycobacterium tuberculosis- An Overview

Mycobacterium tuberculosis (M. tb) is a type of bacteria that causes tuberculosis (TB), a chronic infectious disease that mainly affects the lungs, but can also involve other organs and tissues. TB is one of the oldest and deadliest diseases in human history, and remains a major global health problem. According to the World Health Organization (WHO), TB killed 1.6 million people in 2021, making it the second leading infectious killer after COVID-19.

M. tb was first discovered in 1882 by Robert Koch, a German physician and microbiologist who isolated the bacteria from the sputum of a patient with pulmonary TB. He also demonstrated that M. tb could be transmitted from one person to another through the air, and that it could be cultured on solid media. For his groundbreaking work, Koch was awarded the Nobel Prize in Physiology or Medicine in 1905.

M. tb belongs to the genus Mycobacterium, which comprises more than 200 species of bacteria that share some common features, such as a high content of mycolic acid in their cell walls, which makes them acid-fast, meaning that they retain certain dyes even after being washed with acid. This property helps to identify M. tb under the microscope using special stains, such as the Ziehl-Neelsen stain, which gives them a bright red color against a blue background.

M. tb is an obligate aerobe, meaning that it requires oxygen to grow and survive. It is also a slow-growing bacterium, with a generation time of about 15 to 24 hours, compared to other bacteria that can divide every 20 minutes or less. This slow growth rate makes M. tb difficult to culture and treat with antibiotics, as it can take several weeks to months to obtain visible colonies on solid media or to determine drug susceptibility.

M. tb is also an intracellular pathogen, meaning that it can invade and multiply within host cells, especially macrophages, which are immune cells that normally engulf and destroy foreign particles and microbes. M. tb has evolved various strategies to evade the killing mechanisms of macrophages, such as preventing the fusion of phagosomes with lysosomes, inhibiting the acidification of phagosomes, and modulating the host immune response.

M. tb has a complex genome that consists of about 4.4 million base pairs of DNA and encodes about 4000 genes. The genome contains many repetitive sequences and large regions of difference (RDs) that are deleted or absent in some strains of M. tb compared to others. These RDs can be used as molecular markers to differentiate M. tb strains and to trace their evolutionary history and geographic origin.

M. tb is transmitted from person to person through respiratory droplets that are released when an infected person coughs, sneezes, speaks, or sings. The droplets can remain suspended in the air for several hours and can be inhaled by susceptible individuals who share the same environment. Not everyone who is exposed to M. tb becomes infected or develops TB disease, as this depends on various factors, such as the dose and duration of exposure, the immune status of the host, and the virulence of the strain.

There are two main stages of TB infection: latent TB infection (LTBI) and active TB disease (ATBD). LTBI occurs when M. tb enters the body and is contained by the host immune system, forming granulomas (small nodules) in the lungs or other organs where the bacteria remain dormant but alive for years or decades without causing any symptoms or signs of disease. People with LTBI are not contagious and do not need treatment unless they have a high risk of developing ATBD.

ATBD occurs when M. tb reactivates from latency and starts multiplying and destroying tissue, causing symptoms such as cough, fever, weight loss, night sweats, chest pain, and hemoptysis (coughing up blood). ATBD can also spread from the lungs to other parts of the body through the bloodstream or lymphatic system, causing extrapulmonary TB that can affect organs such as the brain, spine, kidneys, lymph nodes, bones, joints, skin, or eyes.

The diagnosis of TB infection or disease is based on clinical history, physical examination, laboratory tests, and imaging studies. The most common tests for TB infection are the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), which measure the immune response to specific antigens of M. tb in the blood or skin. The most common tests for TB disease are sputum smear microscopy and culture for M. tb , which detect the presence of acid-fast bacilli in respiratory specimens.

The treatment of TB infection or disease involves a combination of antibiotics that are taken for several months to kill all the bacteria and prevent relapse or resistance. The standard regimen for LTBI consists of isoniazid (INH) for 6 to 9 months or rifampin (RIF) for 4 months. The standard regimen for ATBD consists of four drugs: INH , RIF , pyrazinamide (PZA), and ethambutol (EMB) for 2 months followed by INH and RIF for 4 months.

The prevention of TB infection or disease includes various measures such as improving living conditions and ventilation; reducing overcrowding and contact with infectious cases; implementing infection control practices in health care settings; screening high-risk groups for LTBI and offering preventive treatment; providing early diagnosis and effective treatment for ATBD cases; ensuring adherence and completion of therapy; monitoring drug resistance and adverse effects; promoting health education and awareness; and supporting research and development for new drugs , vaccines ,and diagnostics.

Mycobacterium tuberculosis is a bacterium that mainly causes tuberculosis, a chronic infectious disease that affects the lungs and other organs. The bacterium has a complex and unique cell wall that makes it resistant to many environmental stresses and antimicrobial agents.

The natural reservoir of M. tuberculosis is the human host, especially those who have active pulmonary tuberculosis and can transmit the infection through respiratory droplets. The bacterium usually infects the alveolar macrophages, which are immune cells that reside in the lungs and phagocytose foreign particles. However, M. tuberculosis can also spread to other parts of the body through the bloodstream or lymphatic system, and cause extrapulmonary tuberculosis in organs such as the kidneys, spine, brain, lymph nodes, bones, joints, and skin .

M. tuberculosis can also survive outside the human host for prolonged periods of time, depending on the environmental conditions. The bacterium can remain viable for weeks in dust, carpets, or clothes, and for months in sputum. It can also be found in soil and water, where it may interact with other microorganisms or be ingested by animals. However, M. tuberculosis is not considered to be a free-living or opportunistic pathogen, as it requires a human host to complete its life cycle and cause disease.

One of the factors that influences the survival of M. tuberculosis in the environment is its ability to form biofilms, which are aggregates of bacteria that adhere to surfaces and produce extracellular matrix. Biofilms can protect the bacteria from desiccation, UV radiation, pH changes, and antimicrobial agents. M. tuberculosis can form biofilms on various surfaces, such as plastic, glass, metal, or human cells. Biofilms may also play a role in the persistence and latency of M. tuberculosis infection in the human host.

Another factor that affects the habitat of M. tuberculosis is its sensitivity to oxygen levels. M. tuberculosis is an obligate aerobe, meaning that it requires oxygen for its growth and metabolism. However, it can also adapt to low-oxygen or hypoxic conditions, such as those found in granulomas (the lesions formed by the immune system to contain the infection) or in necrotic tissues. Under hypoxia, M. tuberculosis can enter a dormant or non-replicating state, where it reduces its metabolic activity and expresses genes that help it survive stress. This state may also contribute to the latency and reactivation of M. tuberculosis infection in some individuals.

In summary, M. tuberculosis is a bacterium that mainly lives in the human host, but can also survive in various environmental conditions for long periods of time. It can infect different organs and tissues, and adapt to different oxygen levels. It can also form biofilms and enter dormancy to evade host defenses and environmental stresses.

Mycobacterium tuberculosis is a bacterium that belongs to the genus Mycobacterium, which comprises over 150 species of acid-fast bacilli. Acid-fast bacilli are bacteria that retain the red color of the primary stain (carbol fuchsin) after being treated with acid and alcohol in the Ziehl-Neelsen staining technique. This property is due to the presence of a thick, waxy layer of mycolic acids and other lipids in their cell wall, which makes them resistant to many environmental stresses and antimicrobial agents.

Mycobacterium tuberculosis is a straight or slightly curved rod-shaped bacterium, measuring about 0.5 µm in width and 3 µm in length . It is non-sporing, non-motile, and non-capsulated. It can appear as single cells, in pairs, or in small clumps. It has a high content of guanine and cytosine (65%) in its DNA, which makes it more stable and less prone to mutations.

Mycobacterium tuberculosis is an obligate aerobe, meaning that it requires oxygen for its growth and metabolism. It grows very slowly, with a generation time of about 15 to 24 hours. It can survive for weeks in dust, carpets, or clothes, and for months in sputum. It can also be found in soil and water, but its main reservoir is the human host.

Mycobacterium tuberculosis is capable of intracellular growth within macrophages, the immune cells that normally phagocytose and kill bacteria. It can evade the killing mechanisms of the macrophages by preventing the fusion of the phagosome (the vesicle that contains the bacteria) with the lysosome (the organelle that contains digestive enzymes). It can also modulate the immune response of the host by producing various virulence factors, such as mycolic acid, lipoarabinomannan, ESX-1 secretion system, and phagosome maturation factors.

Mycobacterium tuberculosis is the causative agent of tuberculosis, a chronic infectious disease that mainly affects the lungs but can also involve other organs. Tuberculosis is transmitted by inhalation of aerosols containing the bacteria from an infected person. The infection can result in different clinical outcomes depending on the host`s immune status and genetic factors. Some people may develop primary tuberculosis soon after infection, while others may remain asymptomatic and harbor latent tuberculosis for years or decades before reactivation. Tuberculosis is diagnosed by various methods, such as microscopy, culture, biochemical tests, animal inoculation, serology, antigen detection, and molecular techniques. Tuberculosis is treated by a combination of antibiotics for at least six months to prevent relapse and resistance development. Tuberculosis can be prevented by early detection and treatment of infectious cases, reducing overcrowding and improving ventilation, and vaccination with Bacillus Calmette-Guérin (BCG).

Mycobacterium tuberculosis is a slow-growing bacterium that requires special media and conditions for its cultivation. It can grow on both solid and liquid media, but the growth rate and colony morphology may vary depending on the type of medium used. The following are some of the common media and characteristics of M. tuberculosis culture:

• Lowenstein-Jensen (LJ) medium: This is an egg-based medium that contains glycerol, malachite green, and various salts. It is the most widely used medium for the primary isolation of M. tuberculosis from clinical specimens. The growth is usually visible after 2-3 weeks of incubation at 35-37°C in a 5-10% CO2 atmosphere. The colonies are non-pigmented, dry, rough, raised, irregular, and wrinkled, resembling breadcrumbs . They are also called "rough, tough, and buff" colonies. The growth is eugonic, meaning that it is more luxuriant than other mycobacteria.
• Middlebrook 7H10 and 7H11 agar: These are agar-based media that contain oleic acid, albumin, dextrose, catalase, and various salts. They are supplemented with glycerol or pyruvate as carbon sources and polymyxin B, amphotericin B, carbenicillin, and trimethoprim as selective agents to inhibit the growth of contaminants. The growth is faster than on LJ medium, usually within 1-2 weeks of incubation at 35-37°C in a 5-10% CO2 atmosphere. The colonies are non-pigmented, smooth, moist, flat, and circular. They are also called "smooth and shiny" colonies. The growth is dysgonic, meaning that it is less luxuriant than other mycobacteria.
• Middlebrook 7H9 broth: This is a liquid medium that contains oleic acid, albumin, dextrose, catalase, and various salts. It is supplemented with glycerol or pyruvate as carbon sources and polymyxin B, amphotericin B, carbenicillin, and trimethoprim as selective agents to inhibit the growth of contaminants. The growth is faster than on solid media, usually within 1 week of incubation at 35-37°C in a 5-10% CO2 atmosphere. The broth becomes turbid and may form a pellicle or a sediment at the bottom of the tube. The growth can be detected by radiometric methods such as BACTEC or by molecular methods such as PCR.
• Other media: M. tuberculosis can also grow on other media such as Petragnini medium, Dorset medium, Tarshis medium, Loeffler medium, Pawlowsky medium, Dubos` medium, Proskauer and Beck`s medium, Sula`s medium, Sauton`s medium etc., but they are less commonly used than the above-mentioned media. The growth characteristics may vary depending on the composition and pH of the media.

Mycobacterium tuberculosis is an obligate aerobe that requires oxygen for its growth. It does not produce pigments or spores. It has a high content of mycolic acid and lipids in its cell wall that make it resistant to many disinfectants and antibiotics. It also has a complex cell wall structure that makes it acid-fast, meaning that it retains the red color of carbol fuchsin dye after decolorization with acid-alcohol. It can be identified by various biochemical tests such as niacin accumulation test, nitrate reduction test, catalase test etc., or by molecular methods such as PCR or sequencing.

Mycobacterium tuberculosis can be identified by various biochemical tests that detect its metabolic properties and enzymatic activities. Some of the commonly used biochemical tests are :

• Niacin accumulation test: This test is based on the ability of M. tuberculosis to produce and accumulate niacin (nicotinic acid) in the culture medium. Niacin can be detected by adding cyanogen bromide and pyridine, which form a red complex with niacin. M. tuberculosis is niacin positive, whereas most other mycobacteria are niacin negative.
• Arylsulphatase test: This test measures the activity of arylsulphatase, an enzyme that hydrolyzes phenolphthalein disulphate to phenolphthalein, which turns pink in alkaline pH. M. tuberculosis produces arylsulphatase that can be detected after 3 days of incubation, whereas other mycobacteria produce arylsulphatase that can be detected only after 14 days of incubation.
• Neutral red test: This test evaluates the ability of M. tuberculosis to grow in a medium containing neutral red dye, which inhibits the growth of most other bacteria. M. tuberculosis is neutral red positive, meaning that it can grow in the presence of the dye and produce red colonies.
• Catalase peroxidase test: This test assesses the activity of catalase peroxidase, an enzyme that catalyzes the decomposition of hydrogen peroxide to water and oxygen. M. tuberculosis has a weak catalase activity and a positive peroxidase activity, meaning that it produces bubbles when exposed to hydrogen peroxide and turns blue when exposed to potassium iodide and starch.
• Amidase test: This test detects the presence of amidase, an enzyme that hydrolyzes acetamide to ammonia and acetic acid. M. tuberculosis is amidase positive, meaning that it produces ammonia that can be detected by adding Nessler`s reagent, which forms a yellow-brown precipitate with ammonia.
• Nitrate reduction test: This test determines the ability of M. tuberculosis to reduce nitrate to nitrite or nitrogen gas. M. tuberculosis is nitrate positive, meaning that it reduces nitrate to nitrite, which can be detected by adding sulfanilic acid and alpha-naphthylamine, which form a red complex with nitrite.
• Tween 80 hydrolysis: This test evaluates the activity of lipase, an enzyme that hydrolyzes Tween 80 (a polyoxyethylene derivative of oleic acid) to oleic acid and polyoxyethylene sorbitol. M. tuberculosis shows variable results in this test, meaning that some strains can hydrolyze Tween 80 and produce oleic acid that lowers the pH of the medium and changes its color from blue-green to yellow, while others cannot.

These biochemical tests can help differentiate M. tuberculosis from other mycobacteria and confirm its identification after culture and microscopy . However, these tests are time-consuming, labor-intensive, and may not be available in resource-limited settings. Therefore, molecular techniques such as nucleic acid amplification tests (NAATs) and sequencing are preferred for rapid and accurate diagnosis of tuberculosis .

Mycobacterium tuberculosis (Mtb) is a highly successful pathogen that can survive and multiply within the hostile environment of the host macrophages. To achieve this, Mtb has evolved various strategies to evade or modulate the host immune response and to adapt to different stresses. These strategies are mediated by a number of virulence factors that are encoded by Mtb genome and expressed during different stages of infection. Some of the major virulence factors of Mtb are:

• Mycolic acid and Lipoarabinomannan (LAM): These are the main components of the waxy cell wall of Mtb that confer resistance to many antibiotics, disinfectants, and host factors. Mycolic acid is a long-chain fatty acid that forms a hydrophobic barrier around the cell and prevents the fusion of phagosome with lysosome. LAM is a lipopolysaccharide-like molecule that binds to various receptors on macrophages and modulates their signaling pathways. LAM can also inhibit the production of reactive oxygen and nitrogen species, interfere with antigen presentation, and induce cytokine release and apoptosis .

• ESX-1 secretion system: This is a specialized type VII secretion system that delivers various proteins and enzymes into the host cytoplasm. These include ESAT-6 and CFP-10, which are potent T-cell antigens and immunodominant antigens for the diagnosis of tuberculosis. ESX-1 secretion system is essential for the virulence of Mtb as it facilitates the escape of bacteria from the phagosome into the cytosol, where they can replicate and spread to other cells .

• Phagosome maturation factors: These are molecules that interfere with the normal maturation and acidification of the phagosome, where Mtb resides after being engulfed by macrophages. Some examples are Urease, which hydrolyzes urea to produce ammonia and neutralize the phagosomal pH; Superoxide dismutase (SOD), which detoxifies reactive oxygen species; Nla gene product, which inhibits host cell apoptosis; and PhoP/PhoR two-component system, which regulates the expression of many genes involved in phagosome remodeling .

• Cord factor (trehalose dimycolate): This is a glycolipid that is responsible for the characteristic serpentine growth or cording of Mtb in culture. Cord factor has multiple effects on the host immune system, such as inducing granuloma formation, stimulating pro-inflammatory cytokines, activating macrophages and neutrophils, inhibiting phagocytosis, and inducing necrosis .

• Other factors: Mtb also possesses many other factors that contribute to its virulence, such as KatG catalase-peroxidase, which detoxifies hydrogen peroxide and activates isoniazid; PknG serine/threonine kinase, which blocks phagosome-lysosome fusion; ManLAM mannose-capped LAM, which inhibits macrophage activation; PE/PPE proteins, which modulate antigen presentation and T-cell response; Mce proteins, which mediate cholesterol uptake; and DosR regulon, which controls dormancy and persistence .

These virulence factors enable Mtb to establish a chronic infection in the host and cause tuberculosis, a disease that remains a major global health challenge. Understanding the molecular mechanisms of these factors may provide new insights for developing novel vaccines and drugs against tuberculosis.

Pathogenesis is the process by which a microorganism causes disease in a host. In the case of Mycobacterium tuberculosis, the pathogenesis involves several steps that can be divided into three stages: infection, latency, and reactivation.

Infection

Infection occurs when a person inhales droplet nuclei containing tubercle bacilli that reach the alveoli of the lungs. These tubercle bacilli are ingested by alveolar macrophages; the majority of these bacilli are destroyed or inhibited. A small number may multiply intracellularly and are released when the macrophages die.

The bacteria then spread through the lymphatic system and the bloodstream to various organs and tissues, such as the lymph nodes, kidneys, bones, and meninges. This is called hematogenous dissemination and it usually occurs within 6 weeks of infection.

The bacteria trigger a cell-mediated immune response by activating T cells and macrophages. These immune cells form granulomas around the bacteria to isolate and contain them. Granulomas are composed of three zones: a central area of large, multinucleated giant cells containing tubercle bacilli; a mid-zone of pale epithelioid cells often arranged radially; and a peripheral zone of fibroblasts, lymphocytes, and monocytes.

The center of the granuloma contains a mixture of necrotic tissue and dead macrophages. Being metabolically very active, the macrophages in the granuloma consume oxygen, and the resulting anoxia and acidosis in the center of the lesion probably kill most of the bacilli. Granuloma formation is usually sufficient to limit the primary infection.

The lesions become quiescent and surrounding fibroblasts produce dense scar tissue, which may become calcified. This is called a Ghon focus and it is usually found in the lower lobes of the lungs. Programmed cell death (apoptosis) of bacteria-laden macrophages by cytotoxic T cells and natural killer (NK) cells contributes to protective immunity by generating a metabolic burst that kills tubercle bacilli.

Latency

In most infected individuals, the primary infection resolves but some residual tubercle bacilli enter a poorly understood stage of latency or dormancy. This is mostly observed in immunocompetent cases. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB.

The latent bacilli are not actively replicating and are not detectable by conventional microbiological methods. They are also resistant to most anti-TB drugs that target actively growing bacteria. The latent bacilli can persist for years or even decades in a dormant state within granulomas or other cellular niches.

The factors that regulate the transition from active infection to latency and vice versa are not fully understood. However, some possible factors include bacterial factors (such as gene expression, metabolic adaptation, stress response, antigenic variation), host factors (such as immune status, genetic susceptibility, co-infections, hormonal changes), and environmental factors (such as oxygen tension, pH, nutrient availability).

Reactivation

Reactivation of dormant foci of tubercle bacilli or exogenous reinfection leads to post-primary tuberculosis, which differs in several respects from the primary disease. For unknown reasons, reactivation or reinfection tuberculosis tends to develop in the upper lobes of the lungs.

Proteases liberated by activated macrophages soften and liquefy the caseous material, and an excess of tumor necrosis factor and other immunological mediators causes the wasting and fevers characteristic of the disease. The interior of the tuberculoma is acidic and anoxic and contains few viable tubercle bacilli.

Eventually, the expanding lesion erodes through the wall of a bronchus, the liquefied contents are discharged and a well-aerated cavity is formed. The atmosphere of the lung, with a high carbon dioxide level, is ideal for supporting the growth of the bacilli, and huge numbers of these are found in the cavity walls.

Once the cavity is formed, large numbers of bacilli gain access to the sputum, and the patient becomes an open or infectious case. In post-primary tuberculosis, dissemination of bacilli to lymph nodes and other organs is unusual.

Instead, the spread of infection occurs through the bronchial tree so that secondary lesions develop in the lower lobes of the lung and, occasionally, in the trachea, larynx, and mouth. Bacilli in swallowed sputum cause intestinal lesions. Secondary lesions may also develop in the bladder and epididymis in cases of renal tuberculosis. Post-primary cutaneous tuberculosis (lupus vulgaris) usually affects the face and neck.

Tuberculosis (TB) is a disease that mainly affects the lungs, but can also involve other organs and systems of the body. The clinical manifestation of TB depends on the site and extent of infection, the immune status of the host, and the presence of complications. The most common symptoms of TB are:

• A cough that lasts more than three weeks, which may be productive or dry, and may be associated with hemoptysis (coughing up blood or sputum stained with blood) .
• Fever, which may be low-grade or intermittent, and may be accompanied by night sweats or chills .
• Weight loss, anorexia (loss of appetite), fatigue, weakness, and malaise .
• Chest pain, dyspnea (difficulty breathing), or pleural effusion (fluid accumulation in the pleural space) in cases of pulmonary TB with extensive lung involvement or pleural TB .
• Lymphadenopathy (swollen lymph nodes), especially in the cervical region, in cases of extrapulmonary TB involving the lymphatic system .
• Meningitis (inflammation of the membranes covering the brain and spinal cord), which may present with headache, neck stiffness, photophobia (sensitivity to light), altered mental status, seizures, or cranial nerve palsies in cases of extrapulmonary TB involving the central nervous system .
• Pericarditis (inflammation of the membrane surrounding the heart), which may present with chest pain, dyspnea, tachycardia (rapid heart rate), pericardial friction rub (a sound heard on auscultation), or signs of cardiac tamponade (compression of the heart by fluid accumulation) in cases of extrapulmonary TB involving the pericardium .
• Osteomyelitis (infection of the bone) or arthritis (infection of the joint), which may present with bone pain, swelling, deformity, or reduced mobility in cases of extrapulmonary TB involving the skeletal system .
• Genitourinary TB, which may present with dysuria (painful urination), hematuria (blood in urine), flank pain, renal failure, infertility, or pelvic inflammatory disease in cases of extrapulmonary TB involving the genitourinary tract .
• Cutaneous TB, which may present with various skin lesions such as ulcers, nodules, plaques, abscesses, or scars in cases of extrapulmonary TB involving the skin .

The symptoms of TB may be mild or nonspecific at first, and may be mistaken for other conditions such as influenza, bronchitis, pneumonia, or cancer. Therefore, it is important to seek medical attention if you have any persistent or unusual symptoms that could indicate TB. Early diagnosis and treatment can prevent serious complications and transmission of the disease.

Laboratory diagnosis of tuberculosis (TB) is essential for confirming the presence of the bacteria, identifying the species and strain, and determining the drug susceptibility of the isolates. The main methods used for laboratory diagnosis are:

• Microscopy: This is the simplest and most rapid method to detect acid-fast bacilli (AFB) in sputum and other clinical specimens. The Ziehl–Neelsen (ZN) staining technique is commonly used, which stains the bacteria red against a blue background. Fluorescence microscopy, which uses fluorescent dyes to enhance the visibility of AFB, is more sensitive and less tiring than ZN staining. However, microscopy cannot differentiate between different species of mycobacteria or determine their viability or drug resistance.
• Culture: This is the gold standard for laboratory confirmation of TB, as it allows for isolation, identification, and drug susceptibility testing of the bacteria. However, culture is slow and requires biosafety precautions. The most widely used solid medium is Lowenstein-Jensen (LJ) medium, which takes 6-8 weeks to produce visible colonies. Liquid media, such as Middlebrook 7H9 broth or BACTEC, can reduce the time to detection and increase the sensitivity of culture. Molecular methods, such as PCR or hybridization assays, can be used to identify the species and strain of the cultured bacteria.
• Biochemical analysis: This is a traditional method to differentiate between different species of mycobacteria based on their metabolic characteristics, such as niacin accumulation, nitrate reduction, catalase activity, and susceptibility to certain inhibitors. However, biochemical analysis is time-consuming, labor-intensive, and often inconclusive.
• Animal inoculation: This is an obsolete method that involves injecting guinea pigs with clinical specimens and observing them for signs of infection. It is rarely used due to ethical concerns, low sensitivity, and long duration.
• Serodiagnosis: This is a method that detects antibodies against mycobacterial antigens in serum samples. It is based on ELISA or latex agglutination techniques. However, serodiagnosis is not reliable, as it has low sensitivity and specificity, and cannot distinguish between active and latent infection or between different species of mycobacteria.
• Antigen detection: This is a method that detects mycobacterial components or products in clinical samples. For example, tuberculostearic acid is a fatty acid that can be extracted from the cell wall of mycobacteria and detected by gas chromatography or mass spectrometry. Antigen detection can be useful for diagnosing extrapulmonary TB or paucibacillary cases that are negative by microscopy or culture.
• Molecular techniques: These are methods that detect or amplify specific nucleic acid sequences of mycobacteria in clinical samples or cultures. They include PCR-based assays, hybridization assays, nucleic acid amplification tests (NAATs), sequencing, and genotyping. Molecular techniques can provide rapid and accurate identification of the species and strain of mycobacteria, as well as their drug resistance profile. However, they require sophisticated equipment, trained personnel, and quality control measures.

The choice of laboratory method depends on the type and quality of the specimen, the availability of resources, and the clinical context. A combination of methods may be needed to achieve a definitive diagnosis of TB.

Tuberculosis (TB) is a serious infectious disease caused by Mycobacterium tuberculosis that mainly affects the lungs, but can also involve other organs. TB can be cured with proper treatment, but if left untreated, it can be fatal or cause permanent damage.

The treatment of TB depends on several factors, such as the type of TB (active or latent), the drug susceptibility of the TB bacteria, the presence of coexisting medical conditions (such as HIV or diabetes), and the potential for drug-drug interactions. The treatment also requires close monitoring and supervision by health care providers to ensure adherence, effectiveness, and safety.

The standard treatment for active TB caused by drug-susceptible bacteria is a 6-month course of four anti-TB drugs: isoniazid, rifampin, pyrazinamide, and ethambutol. The first two months are called the intensive phase, where all four drugs are taken daily. The next four months are called the continuation phase, where only isoniazid and rifampin are taken daily .

These drugs work by killing or inhibiting the growth of the TB bacteria. They also prevent the development of drug resistance, which occurs when the bacteria mutate and become resistant to one or more of the drugs. Drug resistance can make TB more difficult and costly to treat, and can increase the risk of transmission and death.

The doses of the anti-TB drugs depend on the patient`s age, weight, and kidney function. The drugs may cause side effects such as liver damage, nerve damage, skin rash, nausea, vomiting, and vision problems. Therefore, patients need to take their drugs as prescribed and report any symptoms or adverse reactions to their health care providers.

Some patients may be eligible for a shorter 4-month regimen that consists of rifapentine, moxifloxacin, isoniazid, and pyrazinamide for the first 8 weeks, followed by rifapentine, moxifloxacin, and isoniazid for another 9 weeks . This regimen is recommended for patients who are 12 years or older, weigh at least 40 kg, have pulmonary TB caused by drug-susceptible bacteria, and have no contraindications to this regimen . This regimen has been shown to be as effective as the standard 6-month regimen in curing TB .

The treatment of latent TB infection (LTBI) is aimed at preventing the development of active TB disease in people who have been exposed to or infected with TB bacteria but do not have any symptoms or signs of disease. LTBI can be treated with different regimens that vary in duration and number of drugs. The most common regimens are:

• Isoniazid for 6 or 9 months
• Rifampin for 4 months
• Isoniazid and rifapentine once weekly for 12 weeks
• Isoniazid and rifampin daily for 3 months

The choice of regimen depends on the patient`s preference, adherence, tolerance, and risk factors. The benefits and risks of LTBI treatment should be discussed with the health care provider before starting treatment.

The treatment of drug-resistant TB (DR-TB) is more complex and challenging than the treatment of drug-susceptible TB. DR-TB occurs when the TB bacteria are resistant to one or more of the first-line anti-TB drugs (isoniazid, rifampin, pyrazinamide, ethambutol). DR-TB can be classified into multidrug-resistant TB (MDR-TB), which is resistant to at least isoniazid and rifampin; and extensively drug-resistant TB (XDR-TB), which is resistant to at least isoniazid, rifampin, a fluoroquinolone (such as moxifloxacin), and an injectable agent (such as amikacin) .

The treatment of DR-TB requires a longer duration (usually 18 to 24 months) and a combination of second-line anti-TB drugs that are less effective and more toxic than the first-line drugs . The second-line anti-TB drugs include:

• A later generation fluoroquinolone (such as moxifloxacin)
• An injectable agent (such as amikacin)
• Two or more core second-line agents (such as ethionamide)
• Other agents that may have some activity against TB (such as linezolid)

The selection of the second-line anti-TB drugs depends on the drug susceptibility testing results of the TB bacteria, which may take several weeks or months to obtain. The doses and frequencies of the second-line anti-TB drugs depend on the patient`s weight and kidney function. The second-line anti-TB drugs may cause serious side effects such as hearing loss, kidney damage, psychiatric disorders, bone marrow suppression, and peripheral neuropathy . Therefore, patients with DR-TB need close monitoring and support from health care providers throughout their treatment.

The prevention of TB is based on several strategies that aim to reduce the transmission and progression of TB infection. These strategies include:

• Early detection and effective treatment of active TB cases to reduce infectiousness and transmission
• Contact investigation and screening of people who have been exposed to active TB cases to identify and treat LTBI
• Infection control measures in health care settings and congregate settings (such as prisons) to prevent exposure to TB
• Vaccination with Bacille Calmette-Guérin (BCG) vaccine in countries with high TB burden or risk groups
• Social and environmental interventions to address the underlying determinants of TB such as poverty, malnutrition, overcrowding, HIV/AIDS

TB is a curable disease that requires timely diagnosis, appropriate treatment, and adequate support from health care providers and systems. Patients with TB should adhere to their prescribed treatment regimen until completion and follow up with their health care providers regularly. Patients with TB should also seek medical attention if they experience any worsening symptoms or adverse reactions during their treatment.

Tuberculosis (TB) is a preventable disease caused by bacteria that mainly affect the lungs but can also infect other organs. TB is spread through the air when a person with active TB disease coughs, sneezes, or speaks, and another person inhales the bacteria. TB can cause serious health problems and even death if not treated properly.

There are several ways to prevent TB, such as:

• Vaccination: A vaccine called BCG (bacille Calmette-Guerin) can protect against TB, especially in children. It is more effective in countries where TB is common and less effective in countries where TB is rare. The vaccine is usually given at birth or soon after, but it can also be given later in life if there is a high risk of exposure to TB. The vaccine may cause a positive reaction to the TB skin test, so a TB blood test may be needed to confirm latent TB infection.

• Treatment of latent TB infection: Many people who are infected with TB bacteria do not have any symptoms and are not contagious. This is called latent TB infection. However, they can develop active TB disease later in life, especially if their immune system becomes weak. People who have latent TB infection can take medicine to prevent them from developing active TB disease. There are different types of medicine and treatment regimens for latent TB infection, depending on the person`s age, health condition, and risk factors. The treatment usually lasts from 3 to 9 months. It is important to take the medicine as prescribed and complete the course of treatment.

• Early diagnosis and treatment of active TB disease: People who have symptoms of TB, such as cough, fever, weight loss, or night sweats, should see a doctor as soon as possible. They should also tell the doctor if they have been in contact with someone who has TB or if they have traveled to a country where TB is common. The doctor will perform tests, such as a chest X-ray, a sputum sample, or a blood test, to diagnose TB. If the diagnosis is confirmed, the person will need to take several drugs for 6 to 12 months to cure the infection and prevent the spread of the bacteria. The drugs may have side effects, such as nausea, rash, or liver problems, so the person should report any problems to the doctor and have regular check-ups. The person should also avoid contact with other people until they are no longer contagious, which usually happens after 2 to 4 weeks of treatment.

• Infection control measures: People who have active TB disease should follow some precautions to prevent transmitting the bacteria to others. These include:

  • Covering the mouth and nose with a tissue or a mask when coughing, sneezing, or speaking.
  • Disposing of used tissues in a sealed plastic bag or a closed trash can.
  • Washing the hands with soap and water or using an alcohol-based hand sanitizer after coughing or sneezing.
  • Keeping the windows open and using fans or ventilation systems to improve air circulation in indoor spaces.
  • Avoiding crowded and enclosed places where possible.
  • Taking the prescribed drugs regularly and completing the treatment course.

People who are at high risk of getting infected with TB bacteria should also take some preventive measures, such as:

• Getting tested for latent TB infection if they have been exposed to someone with active TB disease or if they belong to a high-risk group, such as people with HIV infection, diabetes, kidney disease, cancer, or other conditions that weaken the immune system; people who inject illegal drugs; people who work or live in health care settings, prisons, homeless shelters, or other places where TB is common; people who have recently immigrated from countries where TB is common; babies and young children; and elderly people.
• Taking medicine for latent TB infection if prescribed by the doctor.
• Getting vaccinated with BCG if recommended by the doctor.
• Avoiding contact with people who have active TB disease until they are cured.
• Practicing good hygiene habits, such as washing the hands frequently, eating a balanced diet, getting enough sleep, and avoiding smoking and alcohol.

By following these prevention strategies, we can reduce the burden of TB and save lives.

We are Compiling this Section. Thanks for your understanding.